Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xynomic Closes $191.6 Million Merger with Bison Capital; Now Listed on Nasdaq Exchange

publication date: May 15, 2019

Xynomic Pharma has closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC. BCAC, which will change its name to Xynomic, will issue 42,860,772 new common shares of stock to Xynomic’s shareholders, worth $191.6 million. Another $55 million in shares will be available to Xynomic shareholders if certain objectives are met. Xynomic, founded in 2016, is headquartered in the US with operations in Raleigh, North Carolina and Shanghai. The company is developing three in-licensed novel oncology therapeutics in the US, Europe and China. More details....

Stock Symbol: (NSDQ: BCAC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.